Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Annals of Hematology|October 12, 2012
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangementHee-Jin Kim, Hee Kyung Ahn, Chul Won Jung, et al.
The Lancet. Oncology|November 1, 2019
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trialYeon Hee Park, Tae-Yong Kim, Gun Min Kim, et al.
Cancer Research and Treatment|December 14, 2021
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking GroupShinkyo Yoon, Miso Kim, Yong Sang Hong, et al.
Therapeutic Advances in Medical Oncology|November 7, 2022
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study GroupHye Sook Han, Kyoung Eun Lee, Young Ju Suh, et al.
The Lancet. Oncology|February 20, 2025
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 studyHee Kyung Ahn, Ji-Yeon Kim, Kyung-Hun Lee, et al.
The Oncologist|September 8, 2019
A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin ToxicitiesYoung Saing Kim, Jun Ho Ji, Sung Yong Oh, et al.
The Lancet Regional Health. Western Pacific|July 21, 2025
Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)Hee Kyung Ahn, Jee Hung Kim, Su-Jin Koh, et al.
Breast (Edinburgh, Scotland)|August 27, 2022
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, et al.
Cancer Research and Treatment|September 2, 2015
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and HistologyJun Ho Yi, Jung Hun Kang, In Gyu Hwang, et al.
Journal of Cancer Research and Clinical Oncology|February 1, 2021
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05Ji Hyun Park, Gun Lyung You, Myung-Ju Ahn, et al.
Pageof 16